Curis, Inc. company was founded in 2000 and is based in Cambridge, Massachusetts. Curis, Inc., a drug discovery and development company, focuses on the research and development of cancer therapeutics. The company, in collaboration with Genentech, is conducting a pivotal Phase II clinical trial on its lead molecule, GDC-0449 in advanced basal cell carcinoma patients, as well as various Phase II clinical trials in first-line metastatic colorectal cancer and in advanced ovarian cancer patients. It is also evaluating CUDC-101, a small molecule that is in a Phase I clinical testing and is designed to target histone deacetylase (HDAC), epidermal growth factor receptor (EGFR), and epidermal growth factor receptor 2 (Her2). In addition, Curis has a development candidate, CUDC-305, a Heat Shock Protein 90 (Hsp90) inhibitor.

Hikma Pharmaceuticals was founded in 1978 by chairman Samih Darwazah. Hikma Pharmaceuticals Plc is a speciality pharmaceutical company with operations in Europe and the United States and a focus in the Middle East and North Africa (MENA) region. The Company develops, manufactures and markets branded and unbranded generic, as well as in-licensed products in both oral and injectable dosage forms. Its operations are conducted through three segments: Branded Pharmaceuticals, Generic Pharmaceuticals and Injectable Pharmaceuticals. Hikma Pharmaceuticals Plc’s Branded Pharmaceuticals segment develops, manufactures and markets 241 solid, semi-solid and liquid branded pharmaceutical products in 460 dosage strengths and forms, including 33 products under-license from the originator. Injectable Pharmaceuticals segment develops, manufactures and markets 81 injectable products in 202 dosage strengths. Generic Pharmaceuticals develops, manufactures and markets 47 non-branded generic pharmaceutical products in 105 dosage strengths and forms.

Bridgehead International wants to give its clients a head start. The consulting firm operates four divisions that provide a variety of services to a broad spectrum of life science companies and academic groups. Its transaction support division offers technical and commercial advice to firms developing new health care products. Healthcare education services creates medical education and communications programs for the pharmaceutical industry. The market access strategy segment helps companies evaluate competitive pricing and reimbursement models, while opportunity assessment helps firms understand the markets they are attempting to enter. The company operates across Europe, Asia, and North America.

Promega helps researchers plumb the depths of the life sciences. The company sells more than 2,000 products that allow scientists to conduct various experiments in gene, protein, and cellular research. Its reagents and other goods fall into more than two dozen categories, including DNA and RNA purification, genotype analysis, protein expression and analysis, and DNA sequencing. Promega has branches in about a dozen countries around the world. The firm sells its products directly and through more than 50 distributors. Customers include academic, pharmaceutical, and clinical labs, as well as government agencies and energy and chemical companies.

Pharmacyclics, Inc. was founded in 1991 and is headquartered in Sunnyvale, California. Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on developing and commercializing small-molecule drugs for the treatment of immune mediated disease and cancer. Pharmacyclics's products in clinical development includes HDAC Inhibitor for advanced solid tumors, recurrent lymphomas, and sarcoma; Factor VIIa Inhibitor for cancer therapy; B Cell Tyrosine Kinase Inhibitor for the treatment of B-Cell lymphomas, and autoimmune diseases and mast cell diseases; and MGd for primary brain tumor and childhood brain tumors. Its pre-clinical development products comprise B Cell Tyrosine Kinase Inhibitors for autoimmune disease and mast cell disease; and HDAC8 Inhibitors for the treatment of autoimmune and cancer.

Cubist was founded in 1992 and is headquartered in Lexington, Massachusetts. Cubist Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company markets CUBICIN (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides in the United States. It began promoting MERREM I.V. (meropenem for injection) in the U.S. in July 2008. MERREM is an established spectrum antibiotic developed by AstraZeneca. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials; CONSERV-1 and CONSERV-2 for the reduction of blood loss during cardiac surgery; and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the company, in collaboration with Alnylam Pharmaceuticals, Inc., has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam's RNA-interference technology.

Naturewell, Incorporated does not have significant operations. Naturewell company intends to seek business opportunities, including an acquisition or merger with an operating business. Previously, it engaged in the research and development of proprietary healthcare products for various conditions, which comprise primary migraine medication, MIGRASPRAY. Naturewell company is based in San Diego, California.

Lipoxen Plc, a biopharmaceutical company, develops drug and vaccine delivery systems, and proprietary products in the fields of protein drugs, vaccines, and oncology. The company’s product candidates under development include ErepoXen for the treatment to maintain the red blood cell population and prevent anaemia; StimuXen for the treatment of neutropenia; InferoXen for hepatitis C; SuliXen for the treatment of type II diabetes; LipoNeu for streptococcus pneumoniae; LipoTet, an oral liposomal tetanus vaccine; HepaXen to prevent and treat hepatitis B; LipoRab, a rabies vaccine candidate; and LipoTaxen, an anti-cancer drug for the treatment of lung, breast, ovarian, and other cancers. It has operations in the United States, Europe, and India. Lipoxen Plc has a collaboration agreement with Pharmsynthez JSC. The company is based in London, the United Kingdom.

Celgene Corporation company was founded in 1980 and is headquartered in Summit, New Jersey. Celgene Corporation engages in the discovery, development, and commercialization of innovative therapies to treat cancer and immune-inflammatory related diseases primarily in Europe and the United States. Its primary commercial stage products include REVLIMID for the treatment in combination with dexamethasone for multiple myeloma patients, as well as for the treatment of patients with transfusion-dependent anemia; and THALOMID for the treatment in combination with dexamethasone of patients with newly diagnosed multiple myeloma, as well as for the treatment and suppression of cutaneous manifestations of erythema nodosum leprosum.Celgene Corporation company also sells ALKERAN for the palliative treatment of multiple myeloma and of carcinoma of the ovary; VIDAZA, which is used for the treatment of various subtypes of MDS; RITALIN that is used for the treatment of attention deficit hyperactivity disorder; and FOCALIN for the treatment of oncology-related disorders. Its development stage products consist of CC-4047, which is in Phase II trials for the treatment of myelofibrosis and multiple myeloma, and in Phase I trials for the treatment of hemoglobinopathies; CC-10015 that is in pre-clinical stage for the treatment of inflammatory diseases; CC-10004, which is in Phase II clinical trials for the treatment of psoriasis, psoriatic arthritis, and inflammatory diseases; JNK CC-930 that is in Phase I trial to treat fibrotic diseases; Amrubicin, which is in Phase III trials for small cell lung cancer treatment; Human umbilical cord blood, a Phase I trials product to treat transplants and hematological disorders; and ACE-011, a Phase II initiated product for multiple myeloma/Bone loss treatment. Celgene Corporation has strategic collaborations with Acceleron Pharma, Inc. for the joint development and commercialization of ACE-011; and GlobeImmune Inc. to develop molecular immunotherapy for the treatment of cancer.

Since its inception in 1740, Whatman knows what it takes to separate the wheat from the chaff. Whatman company makes filters, membranes, and specialty products for applications in the analytical, health care, and bioscience markets in some 70 countries. Whatman company's products can be found in medical devices and diagnostic testing kits. Whatman has also developed technology for the isolation, transportation, storage, and purification of DNA for gathering genetic information. Whatman makes other products such as blotting papers, syringe filters, and chromatography products. Whatman company was acquired by GE Healthcare in 2008.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.